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Summary of recent advances 
Tumorigenesis is a multistep process in which the accumulation of genetic alterations drives 
the transformation of normal cells into malignant derivatives. Activation-induced cytidine 
deaminase (AID) contributes to immune system diversity by inducing somatic hypermutations 
and class-switch recombinations of human immunoglobulin genes. The mutagenic activity of 
AID, however, can also induce genetic changes in various genes and may lead to the 
development of cancer. Helicobacter pylori, a class 1 carcinogen for human gastric cancer, 
affects AID expression by two different mechanisms, introduction of bacterial virulence factors 
into host cells and induction of inflammatory responses, thereby contributing to the accumulation 
of mutations in tumor-related genes. Aberrant AID activity may therefore be a novel link 





Helicobacter pylori (H.pylori) is a gram-negative, spiral-shaped bacterium colonized in 
human populations for more than 58,000 years [1]. H.pylori infection is involved in the 
development of several human diseases, including gastro-duodenal ulcers, gastric cancer, and 
mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach. H.pylori strains exhibit a 
high level of genetic diversity, and a striking difference among strains is the presence or absence 
of a 40-kb DNA segment, termed the cag pathogenicity island (PAI). The risk for developing 
H.pylori infection-mediated gastric disorders is closely associated with the strain [2]. The risk of 
developing gastric cancer is higher in patients infected with cagPAI-positive H.pylori compared 
with cagPAI-negative H.pylori [3,4], but how H.pylori infection contributes to gastric 
carcinogenesis remained unknown. Genetic changes in tumor-related genes are essential in the 
malignant transformation that leads to cancer cell development. How the intra-gastric residential 
bacteria induce the genetic changes required for tumorigenesis in host gastric epithelial cells is 
unclear, since the extracellular habitant H.pylori cannot directly access host genomic DNA 
located in the nucleus of gastric epithelial cells. Recent studies, however, revealed that 
cagPAI-positive H.pylori manipulates the host nucleotide editing enzymes to induce mutagenesis 
in human DNA sequences of the gastric epithelium [5].  
 
Novel mechanism of active mutagenesis achieved by nucleotide editing enzymes. 
Genetic changes in tumor-related genes are essential for malignant transformation in cancer 
cell development. Mechanisms that account for genetic changes required for tumorigenesis are 
unknown, except for defects in the DNA repair system that are observed in certain human 
cancers. Several enzymes that induce nucleotide alterations were recently identified, providing a 
new avenue for understanding the mutagenesis mechanism. The apolipoprotein B mRNA editing 
enzyme catalytic polypeptide (APOBEC) family comprises nucleotide editing enzymes that 
insert nucleotide alterations in target DNA or RNA through cytidine deamination [6]. The human 
APOBEC family consists of APOBEC1, -2, -3A, -3B, -3C, -3DE, -3F, -3G, -3H, -4, and 
activation-induced cytidine deaminase (AID), and contributes to producing various favorable 
physiologic outcomes by modifying target gene sequences. For example, APOBEC1 participates 
in lipid metabolism through deaminating a specific cytidine to uridine in the Apo-B mRNA, 
resulting in the formation of a termination codon, which leads to the production of a half-length 
genomically-encoded Apo-B100. APOBEC3G is an anti-viral molecule that induces 
hypermutation in viral DNA sequences and acts as a host defense factor against viruses such as 
HIV-1. Although the majority of APOBEC family members exhibit mutagenic activity against 
human RNA or exogenous viral genomes, only AID has the ability to induce nucleotide 
alterations and double-strand DNA breaks in human genomic sequences. Under physiologic 
conditions, AID is expressed in germinal center B-cells and induces somatic hypermutation and 
class-switch recombination of immunoglobulin genes, thereby amplifying immune system 
diversity[7]. In sharp contrast to the favorable role of AID in the immune system, excessive AID 
activity might affect non-immunoglobulin genes, including tumor-related genes in non-lymphoid 
cells [8]. 
 
CagPAI-positive H.pylori induces aberrant AID expression in gastric epithelial cells. 
AID can alter host genomic information, but there are safeguard mechanisms that restrict its 
potential tumorigenic activity, including post-transcriptional regulation by microRNA [9-11], 
post-translational modification by protein phosphorylation or ubuiquitination [12-14], and 
regulation of subcellular localization [15-18].  Restriction of AID expression is also an 
important regulatory system that minimizes the aberrant mutagenic activity of AID. AID gene 
transcription is restricted mainly to activated germinal center B lymphocytes where editing of the 
immunoglobulin gene is required[19,20], while AID expression is not detected in normal 
epithelial cells under physiologic conditions. How then is AID expressed in epithelial cells under 
pathologic conditions, especially where the tumorigenic risk is unusually high? Strikingly, 
endogenous AID is expressed in the epithelial cells of H.pylori -infected stomach. Gastric 
epithelial cells and some infiltrating lymphocytes are immunoreactive for AID protein expression 
in the majority of chronic gastritis tissues infected with cagPAI-positive H.pylori [21]. Moreover, 
eradication of H.pylori infection by antibiotics substantially decreases AID protein expression in 
gastric mucosa. These findings suggest that cagPAI-positive H.pylori somehow upregulates AID 
protein in the gastric epithelium of the infected host.  
CagPAI contain approximately 30 putative genes encoding various bacterial proteins such as 
cytotoxin-associated gene A (cagA) [22].  CagPAI-positive H.pylori introduces several bacterial 
virulence factors into gastric epithelial cells through a type-IV secretion apparatus, and 
cagPAI-positive H.pylori -derived peptidoglycans introduced into the host cells has been shown 
to be responsible for activating the transcription factor NF-B [23]. The AID promoter region 
also includes sites for several transcription factors, such as NF-B, STAT6, HoxC4, Sp1, Sp3, 
and Pax5 [24-27],  and AID expression in B lymphocytes is induced in response to NF-B 
activation through CD40 ligand signaling [28]. Together, these findings suggest that 
cagPAI-positive H.pylori induces AID expression via NF-B activation by introducing bacterial 
virulence factors, and that the proinflammatory response caused by H.pylori infection also 
triggers AID expression via the activation of NF-B in gastric epithelium, because 
proinflammatory cytokines such as tumor necrosis factor (TNF)-and IL-1can induce NF-B 
activation in various types of cells. These hypotheses are supported by in vitro analyses showing 
that AID expression is induced in response to cagPAI-positive H.pylori infection or stimulation 
with the proinflammatory cytokine TNF- via NF-B signaling in cultured human gastric 
epithelial cells [21]. Based on the clinical course of H.pylori-infected individuals, both bacterial 
factors that are introduced into epithelial cells and the inflammatory response against H.pylori 
infection would be responsible for aberrant AID expression in gastric epithelium (Figure 1), and 
the direct action of the bacterial virulence factors contributes to activate AID in the early stage of 
H.pylori infection when the number of bacteria is high. In the late phase of chronic gastritis, 
when gastric atrophy has progressed and the number of H.pylori is decreased, the 
proinflammatory cytokine plays a central role in causing the constitutive expression of AID in 
gastric epithelial cells. 
 
AID induces DNA mutations in tumor-related genes in gastric epithelial cells. 
The target of AID-mediated genotoxic effects is not restricted to immunoglobulin genes and 
several non-immunoglobulin genes are also targeted by AID in lymphocytes. Approximately 
25% of expressed non-immunoglobulin genes analyzed, including Bcl6 and Cd83, accumulated 
AID-mediated mutations in germinal B cells [29]. Moreover, AID produces double-strand DNA 
breaks throughout the genome, including c-myc in B cells [30,31]. The impact of AID expression 
in non-lymphoid gastrointestinal epithelial cells was clarified using mouse model with 
constitutive and ubiquitous AID expression. AID transgenic mice accumulated somatic mutations 
in various tumor-related genes and developed tumors in both lymphoid and non-lymphoid tissues 
[32,33]. The tumors developed in the epithelial organs of AID transgenic mice included lung, 
liver, and gastric cancers.  
The findings that AID mutagenic activity results in stomach cancer led us to speculate that 
H.pylori infection in association with aberrant AID expression contributes to human 
carcinogenesis via the accumulation of genetic alterations in gastric epithelial cells[21]. In in 
vitro-cultured gastric epithelial cells, cagPAI-positive H.pylori infection led to somatic mutations 
in the tumor-suppressor TP53 gene. The number of nucleotide alterations observed in 
H.pylori-infected cells was significantly reduced by knockdown of endogenous AID, indicating 
that the somatic mutations in the TP53 gene in cells infected with cagPAI-positive H.pylori were 
due to the induction of endogenous AID expression in gastric cells.  In wild-type mice, oral 
infection with cagPAI-positive H.pylori upregulated AID protein expression. Moreover, 
nucleotide alterations emerge in the TP53 gene in stomach tissues after oral H.pylori infection in 
wild-type mice. These findings strongly suggest that H.pylori infection causes accumulation of 
somatic mutations in tumor-related genes such as TP53 through aberrant upregulation of AID in 
gastric epithelial cells. 
 
H.pylori-associated lymphoid tumorigenesis and AID expression 
Low-grade lymphomas originating from MALT develop in the stomach, salivary and thyroid 
glands, bronchi, and small intestine, and are classified as MALT lymphoma [34,35]. The 
acquisition of MALT is induced prior to the development of lymphoma as a response to a 
persistent antigenic stimulation [36]. The development of gastric MALT lymphoma, a 
representative gastric lymphoma, is strongly associated with H.pylori infection [37]. The 
seroprevalence of H.pylori is higher in patients with gastric MALT lymphomas than in control 
patients without MALT lymphoma [38], and eradication of H.pylori leads to complete regression 
of the lymphoma in nearly 80% of patients with early-stage disease [39,40].  On the other hand, 
several studies have aimed to clarify the role of AID in the development of MALT lymphoma, 
because AID is required for the development of germinal center-derived non-Hodgkin’s 
lymphomas [41,42].  AID mRNA was, however, expressed in only some extranodal marginal 
zone B-cell MALT lymphomas [41]. More recent studies demonstrate that neoplastic marginal 
zone B cells did not express detectable AID, whereas AID expression was confined to reactive 
areas within MALT lymphomas [43,44]. In addition to the low frequency of AID upregulation in 
MALT lymphoma tissues, it remains unknown whether H.pylori infection enhances the aberrant 
mutagenic activity of AID in gastric B-cells. Further analyses are required to determine the role 




The discovery of AID was a seminal finding that greatly advanced our understanding of the 
molecular mechanisms involved in immunoglobulin diversification [45]. Now, AID is central to 
our understanding of how inflammation and infection underlie the genetic alterations required for 
carcinogenesis in epithelial cells [46].  Indeed, proinflammatory cytokine induction of AID 
expression via the NF-B pathway is not limited to gastric epithelial cells. AID expression is 
mediated by the inflammatory response in a variety of epithelial cells, including human 
hepatocytes [47,48], and biliary[49] and colonic epithelial cells[50].  Aberrant AID expression 
in these gastrointestinal organs results in somatic mutations in various tumor-related genes. Thus, 
AID may have a central role in genetic susceptibility to mutagenesis, which leads to cancers in 
these gastrointestinal tissues upon exposure to certain inflammation or infection (Figure 2).  
A characteristic of H.pylori-associated gastric cancer is multicentric tumor development. 
Patients with a history of H.pylori-related gastric cancer are at high risk for subsequent 
development of gastric cancers[51], suggesting that each epithelial cell of the H.pylori-infected 
stomach possesses sufficient genetic damage for malignant transformation. Efficient strategies to 
restrict aberrant AID activity might help to prevent carcinogenesis in gastric epithelial cells 
inflamed by H.pylori infection.  
References 
1. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, Falush D, Stamer C, Prugnolle F, 
van der Merwe SW, et al.: An African origin for the intimate association between humans and 
Helicobacter pylori. Nature 2007, 445:915-918. 
2. Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009, 
136:1863-1873. 
3. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH: Meta-analysis of the relationship between 
cagA seropositivity and gastric cancer. Gastroenterology 2003, 125:1636-1644. 
4. Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti 
M, Nitti D, et al.: Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. 
Gastroenterology 2008, 135:91-99. 
5. Chiba T, Marusawa H: A novel mechanism for inflammation-associated carcinogenesis; an 
important role of activation-induced cytidine deaminase (AID) in mutation induction. J Mol Med 
2009, 87:1023-1027. 
6. Conticello SG: The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008, 9:229. 
7. Shivarov V, Shinkura R, Doi T, Begum NA, Nagaoka H, Okazaki IM, Ito S, Nonaka T, Kinoshita K, 
Honjo T: Molecular mechanism for generation of antibody memory. Philos Trans R Soc Lond B Biol 
Sci 2009, 364:569-575. 
8. Kinoshita K, Nonaka T: The dark side of activation-induced cytidine deaminase: relationship with 
leukemia and beyond. Int J Hematol 2006, 83:201-207. 
9. Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, 
San-Martin BR, Heidkamp G, Schwickert TA, et al.: MicroRNA-155 suppresses activation-induced 
cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008, 28:630-638. 
10. Teng G, Hakimpour P, Landgraf P, Rice A, Tuschl T, Casellas R, Papavasiliou FN: MicroRNA-155 
is a negative regulator of activation-induced cytidine deaminase. Immunity 2008, 28:621-629. 
*11. de Yebenes VG, Belver L, Pisano DG, Gonzalez S, Villasante A, Croce C, He L, Ramiro AR: 
miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 2008, 
205:2199-2206. 
*References 9 and 10* demonstrate microRNA-155 (miR-155) is upregulated in B lymphocytes 
undergoing class-switch recombination and regulate the transcription of AID by targeting the 3’ 
untranslated region of the AID mRNA, suggesting the possible role of miR-155 as a tumor 
suppressor by inhibiting the genotoxic effect of AID. Similarly, reference 11 showed the 
negative regulation of AID transcription by another microRNA-181b. 
 
12. McBride KM, Gazumyan A, Woo EM, Schwickert TA, Chait BT, Nussenzweig MC: Regulation of 
class switch recombination and somatic mutation by AID phosphorylation. J Exp Med 2008, 
205:2585-2594. 
13. Cheng HL, Vuong BQ, Basu U, Franklin A, Schwer B, Astarita J, Phan RT, Datta A, Manis J, Alt 
FW, et al.: Integrity of the AID serine-38 phosphorylation site is critical for class switch 
recombination and somatic hypermutation in mice. Proc Natl Acad Sci U S A 2009, 106:2717-2722. 
14. Aoufouchi S, Faili A, Zober C, D'Orlando O, Weller S, Weill JC, Reynaud CA: Proteasomal 
degradation restricts the nuclear lifespan of AID. J Exp Med 2008, 205:1357-1368. 
15. Patenaude AM, Orthwein A, Hu Y, Campo VA, Kavli B, Buschiazzo A, Di Noia JM: Active nuclear 
import and cytoplasmic retention of activation-induced deaminase. Nat Struct Mol Biol 2009, 
16:517-527. 
16. Geisberger R, Rada C, Neuberger MS: The stability of AID and its function in class-switching are 
critically sensitive to the identity of its nuclear-export sequence. Proc Natl Acad Sci U S A 2009, 
106:6736-6741. 
17. Casellas R, Yamane A, Kovalchuk AL, Potter M: Restricting activation-induced cytidine 
deaminase tumorigenic activity in B lymphocytes. Immunology 2009, 126:316-328. 
18. Ito S, Nagaoka H, Shinkura R, Begum N, Muramatsu M, Nakata M, Honjo T: Activation-induced 
cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing 
catalytic polypeptide 1. Proc Natl Acad Sci U S A 2004, 101:1975-1980. 
19. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T: Specific 
expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing 
deaminase family in germinal center B cells. J Biol Chem 1999, 274:18470-18476. 
20. Muto T, Muramatsu M, Taniwaki M, Kinoshita K, Honjo T: Isolation, tissue distribution, and 
chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. 
Genomics 2000, 68:85-88. 
21. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, 
Honjo T, Chiba T: Helicobacter pylori infection triggers aberrant expression of activation-induced 
cytidine deaminase in gastric epithelium. Nat Med 2007, 13:470-476. 
22. Hatakeyama M: Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 2009, 44:239-248. 
23. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Memet S, Huerre 
MR, Coyle AJ, et al.: Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag 
pathogenicity island. Nat Immunol 2004, 5:1166-1174. 
24. Crouch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gourzi P, Montano C, Feigenbaum L, Wilson P, 
Janz S, Papavasiliou FN, et al.: Regulation of AID expression in the immune response. J Exp Med 
2007, 204:1145-1156. 
25. Yadav A, Olaru A, Saltis M, Setren A, Cerny J, Livak F: Identification of a ubiquitously active 
promoter of the murine activation-induced cytidine deaminase (AICDA) gene. Mol Immunol 2006, 
43:529-541. 
26. Park SR, Zan H, Pal Z, Zhang J, Al-Qahtani A, Pone EJ, Xu Z, Mai T, Casali P: HoxC4 binds to the 
promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA 
recombination and somatic hypermutation. Nat Immunol 2009, 10:540-550. 
27. Tran TH, Nakata M, Suzuki K, Begum NA, Shinkura R, Fagarasan S, Honjo T, Nagaoka H: B 
cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of 
silencers. Nat Immunol 2010, 11:148-154. 
28. Dedeoglu F, Horwitz B, Chaudhuri J, Alt FW, Geha RS: Induction of activation-induced cytidine 
deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int 
Immunol 2004, 16:395-404. 
**29. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, Schatz DG: Two levels of 
protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845. 
**By extensive sequencing of murine B cell genes, the authors demonstrate that AID acts 
broadly on the genome and approximately 25% of expressed genes analyzed in this study 
accumulated mutations possibly induced by AID activity in germinal centre B cells. 
 
30. Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S, Bolland DJ, 
Chen HT, Corcoran AE, Nussenzweig A, et al.: AID is required for the chromosomal breaks in c-myc 
that lead to c-myc/IgH translocations. Cell 2008, 135:1028-1038. 
*31. Robbiani DF, Bunting S, Feldhahn N, Bothmer A, Camps J, Deroubaix S, McBride KM, Klein IA, 
Stone G, Eisenreich TR, et al.: AID produces DNA double-strand breaks in non-Ig genes and mature 
B cell lymphomas with reciprocal chromosome translocations. Mol Cell 2009, 36:631-641. 
*Demonstration of the capacity of AID to produce paired DNA double-strand break throughout 
the genome which can lead to lymphoma-associated chromosome translocation in mature B 
cells. 
 
32. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T: Constitutive 
expression of AID leads to tumorigenesis. J Exp Med 2003, 197:1173-1181. 
33. Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, Chiba T: Organ-specific profiles 
of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J 
Cancer 2008, 123:2735-2740. 
34. Isaacson P, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive 
type of B-cell lymphoma. Cancer 1983, 52:1410-1416. 
35. Zucca E, Bertoni F, Roggero E, Cavalli F: The gastric marginal zone B-cell lymphoma of MALT 
type. Blood 2000, 96:410-419. 
36. Suarez F, Lortholary O, Hermine O, Lecuit M: Infection-associated lymphomas derived from 
marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006, 107:3034-3044. 
37. Isaacson PG, Du MQ: MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004, 
4:644-653. 
38. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, 
Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994, 
330:1267-1271. 
39. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, Vaira 
D: Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled 
data analysis. Am J Gastroenterol 2009, 104:1932-1937; quiz 1938. 
40. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG: Regression of 
primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after 
eradication of Helicobacter pylori. Lancet 1993, 342:575-577. 
41. Greeve J, Philipsen A, Krause K, Klapper W, Heidorn K, Castle BE, Janda J, Marcu KB, 
Parwaresch R: Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin 
lymphomas. Blood 2003, 101:3574-3580. 
*42. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC, 
3rd, Nussenzweig MC, Dalla-Favera R: AID is required for germinal center-derived 
lymphomagenesis. Nat Genet 2008, 40:108-112. 
*By crossing the mouse model of B cell lymphoma with the AID deficient mouse, the authors 
showed that AID deficiency prevents Bcl6-dependent, germinal center-derived B cell 
lymphomas. 
 
43. Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P, Challacombe S, De Vita S, 
Valesini G, Spencer J, et al.: Activation-induced cytidine deaminase expression in follicular 
dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid 
neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren's syndrome. J Immunol 
2007, 179:4929-4938. 
44. Deutsch AJ, Aigelsreiter A, Staber PB, Beham A, Linkesch W, Guelly C, Brezinschek RI, 
Fruhwirth M, Emberger W, Buettner M, et al.: MALT lymphoma and extranodal diffuse large B-cell 
lymphoma are targeted by aberrant somatic hypermutation. Blood 2007, 109:3500-3504. 
45. Delker RK, Fugmann SD, Papavasiliou FN: A coming-of-age story: activation-induced cytidine 
deaminase turns 10. Nat Immunol 2009, 10:1147-1153. 
46. Marusawa H: Aberrant AID expression and human cancer development. Int J Biochem Cell Biol 
2008, 40:1399-1402. 
47. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watashi K, Shimotohno 
K, Honjo T, Chiba T: Expression of activation-induced cytidine deaminase in human hepatocytes via 
NF-kappaB signaling. Oncogene 2007, 26:5587-5595. 
**48. Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H, Yamada S, Okazaki IM, 
Honjo T, Chiba T, et al.: A novel mouse model of hepatocarcinogenesis triggered by AID causing 
deleterious p53 mutations. Oncogene 2008. 
**Pioneering study demonstrating the critical role of mutational accumulation in immature stem 
cells on the development of cancer cells. The authors show that constitutive AID expression in 
cells producing a marker of immature hepatocytes resulted in the appearance of hepatocellular 
carcinoma. 
 
49. Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, 
Chiba T: Activation-induced cytidine deaminase links bile duct inflammation to human 
cholangiocarcinoma. Hepatology 2008, 47:888-896. 
*50. Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, Kinoshita K, Honjo T, Chiba T: 
Activation-induced cytidine deaminase links between inflammation and the development of 
colitis-associated colorectal cancers. Gastroenterology 2008, 135:889-898, 898 e881-883. 
*The authors show that AID expression in human colonic epithelial cells is induced in response 
to Th2-driven cytokines IL-4 and IL-13, which are activated in inflammatory bowel disease. This 
is the first study to provide the possible link between colonic inflammation, AID expression and 
colorectal cancer development. 
 
51. Aoi T, Marusawa H, Sato T, Chiba T, Maruyama M: Risk of subsequent development of gastric 
cancer in patients with previous gastric epithelial neoplasia. Gut 2006, 55:588-589. 
 
 
